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Abstract
Human placental multipotent mesenchymal stromal cells (hPMSCs) can be isolated from term placenta, but their angiogenic
ability and the regulatory pathways involved are not known. hPMSCs were shown to express integrins av, a4, a5, b1, b3, and
b5 and could be induced to differentiate into cells expressing endothelial markers. Increases in cell surface integrins a5 and
b1, but not a4, avb3,o ravb5, accompanied endothelial differentiation. Vascular endothelial growth factor-A augmented the
effect of fibronectin in enhancing adhesion and migration of differentiated hPMSC through integrin a5b1, but not avb3 or
avb5. Formation of capillary-like structures in vitro from differentiated cells was inhibited by pre-treatment with function-
blocking antibodies to integrins a5 and b1. When hPMSCs were seeded onto chick chorioallantoic membranes (CAM),
human von Willebrand factor-positive cells were observed to engraft in the chick endothelium. CAMs transplanted with
differentiated hPMSCs had a greater number of vessels containing human cells and more incorporated cells per vessel
compared to CAMs transplanted with undifferentiated hPMSCs, and overall angiogenesis was enhanced more by the
differentiated cells. Function-blocking antibodies to integrins a5 and b1 inhibited angiogenesis in the CAM assay. These
results suggest that differentiated hPMSCs may contribute to blood vessel formation, and this activity depends on integrin
a5b1.
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Introduction
Multipotent mesenchymal stromal cells from different adult and
fetal tissues have been shown to have the potential to differentiate
into endothelial cells [1–4]. Human placental multipotent
mesenchymal stromal cells (hPMSCs) express genes associated
with ectoderm, endoderm and mesoderm, including hematopoi-
etic/endothelial cell-related transcripts [5]. They can differentiate
into osteogenic, adipogenic, chondrogenic, and neurogenic cell
lineages [6–8], and, under the combined influence of growth
factors and mechanical shear stress, have been reported to acquire
aspects of the endothelial phenotype [9]. However, the angiogenic
ability of these cells is not well characterized.
Angiogenesis is a complex process that involves extracellular
matrix (ECM) remodeling, endothelial cell differentiation, migra-
tion and proliferation, and the functional maturation of new
endothelial cell colonies into mature blood vessels [10]. There is
evidence that fibronectin is a key ECM component at several
stages, initially providing attachment sites for precursor cells
[11,12], then promoting vascular endothelial growth factor
(VEGF)-induced differentiation to endothelial cells [13]. Further-
more, fibronectin associated with VEGF–A enhances endothelial
cell migration [14]. Targeted gene deletion studies have revealed
that fibronectin functions in vascular stabilization and branching
morphogenesis in the murine embryo [15–18], while a more
restricted gene targeting approach that deletes alternatively spliced
variants of fibronectin leads to defective placental angiogenesis
[19]. Fibronectin is abundant in the mesenchymal compartment of
human placenta where vasculogenesis and angiogenesis occur
[20].
Integrin a5b1 is a selective high affinity receptor for fibronectin,
and a regulator of VEGF-A signaling [21]. Integrin a5b1 is
observed to have an essential role in pathological neovasculariza-
tion in cornea [22] and is up-regulated in newly growing vessels in
embryos and tumors [21,23,24]. Vascularization in the placenta is
critical for normal delivery of nutrients to the fetus. Placental
growth is most rapid in the first half of pregnancy, but
development of the vascular tree continues to term [25,26].
Placental vascular defects, including reduced vessel density, are
associated with fetal growth restriction [27,28]. VEGF-A is
thought to play an important role in human placental vascular-
ization, especially in the early stages [29].
Improved understanding of the cellular and molecular mech-
anisms of placental vasculogenesis and angiogenesis could
potentially lead to treatments to achieve improved pregnancy
outcome as well as the possibility of using placental progenitor cells
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investigate if hPMSCs are capable of functional differentiation into
endothelial cells, and to investigate the role in this process of
integrin a5b1 and its interaction with fibronectin in the presence of
VEGF-A.
Materials and Methods
Isolation and culture, of placenta-derived cells
Clinically normal human placentas (37 to 40 weeks of gestation,
n=30) were obtained after cesarean section. Tissue was collected
after written informed consent was obtained, and this study was
approved by the Institutional Review Board of Mackay Memorial
Hospital, Taipei. The animal studies were specifically approved by
the ethics committee of Mackay Memorial Hospital for animal
experimentation and were conducted following the institution’s
guidelines for animal husbandry.
Isolation of hPMSCs was performed as we described previously
[30]. Briefly, about 100 g of tissue from central placental
cotyledons was minced, trypsinized (0.05% trypsin-EDTA solu-
tion; Invitrogen), and treated with 10 U/ml DNase I (Sigma-
Aldrich) in Dulbecco’s modified Eagle’s medium (DMEM; Gibco)
at 37uC for 5 min several times, and finally filtered through a cell
strainer (BD Biosciences). The supernatants were pooled and
centrifuged, and the mononuclear cells in the supernatants were
recovered by Percoll density gradient fractionation (1.073 g/ml,
Sigma-Aldrich) [31]. The cells were resuspended and seeded in a
flask, and were maintained in DMEM with 10% fetal bovine
serum (FBS; Hyclone) at 37uC in a humidified atmosphere with
5% CO2. Approximately 2 to 3 weeks later, some colonies
containing fibroblast-like cells were observed. These cells were
trypsinized and replated for expansion after 70% confluence.
Flow cytometry
The cell phenotype of hPMSCs was characterized by a panel of
PE- or FITC-conjugated antibodies purchased from Serotec,
Calbiochem, Chemicon, R&D systems, GeneTex, or BD Biosci-
ences using standard fluorescence-activated cell sorting analysis
and CellQuest software. The cells were permeabilized using BD
Cytofix/Cytoperm
TM Fixation/Permeabilization Kit (BD) accord-
ing to the manufacturer9s recommendation before flow cytometry
assay for Oct-4 (Chemicon).
Alterations of integrin abundance on the cell surface of hPMSCs
were evaluated by fluorescence intensity, an index of the surface
concentration of integrin per cell. Mean fluorescence is the
estimated x axis value at maximum peak height. This parameter is
measured independently from the proportion of positive cells,
estimated as the difference between the mean fluorescence (the
surface concentration of integrin molecules) of positive cells and
that of the control samples, regardless of the frequency of positive
cells [32].
Reverse-transcription PCR (RT-PCR)
The following primers were used for PCR reactions: human Oct-4
sense, 59-CGTGAAGCTGGAGAAGGAGAAGCTG-39;a n t i s e n s e ,
59-CAAGGGCCGCAGCTTACACATGTTC-39;h o m e o b o xt r a n -
scription factor nanog (Nanog) sense, 59-AATACCTCAGCCTC-
CAGCAGATG-39; anti-sense, 59-CTGCGTCACACCATTGC-
TATTCT-39; Sry-Box 2 (Sox-2) sense 59-GGCAGCTACAGC-
ATGATGCAGGAGC-39;a n t i s e n s e ,5 9-CTGGTCATGGAGT-
TGTACGCAGG-39;C D 3 1s e n s e ,5 9-GACGTGCTGTTTTA-
CAACATCTC-39;a n t i s e n s e ,5 9-CCTCACGATCCCACCTTGG-
39;C D 3 4s e n s e ,5 9-GCGCTTTGCTTGCTGAGTTT-39;a n t i s e n s e ,
59-GCCATGTTGAGACACAGGGT-39; VE-cadherin sense,
59-GGGAGACCACGCCTCTGTC-39;a n t i s e n s e ,5 9-GGAGGC-
CCTGGGCATCTC-39; VEGFR (vascular endothelial growth factor
receptor)-1 sense, 59-GAAGGCATGAGGATGAGAGC-39;a n t i -
sense, 59-CAGGCTCATGAACTTGAAAGC-39;V E G F R - 2s e n s e ,
59-GGCCAAGTGATTGAAGCAGATG-39;a n t i s e n s e ,5 9-TTCA-
GATCCACAGGGATTGCTC-39; human von Willebrand factor
(vWF) sense, 59-ACGTGATCCTTCTCCTGGATG-39;a n t i s e n s e ,
59-TTCACCACGTTGGAGTCGCCT-39; human CD105 sense,
59-CAACATGCAGATCTGGACCAC-39;a n t i s e n s e ,5 9-CTTTAG-
TACCAGGGTCATGGC-39; 18S sense, 59-TAGAGCTAATA-
CATGCCGACGG-39;a n t i s e n s e ,5 9-GGGCCTCGAAAGAGTCC-
TGTATT-39. The RT-PCR reactions were performed as previously
described [4,33–37].
Differentiation induction
Induction of osteogenic or adipogenic differentiation.
hPMSC cells in passages 6 through 10 (n=5) were cultured in either
osteogenic medium consisting of DMEM containing 10% FBS
(Hyclone), 0.1 mM dexamethasone, 10 mM b-glycerol phosphate,
500 mM ascorbic acid (Sigma-Aldrich) or adipogenic medium
consisting of DMEM containing 10% FBS (Hyclone), 1 mM
dexamethasone, 500 mM isobutylmethylxanthine, 200 mM
indomethacin, and 10 mg/ml insulin (Sigma-Aldrich) [4,7]. The
medium was changed every 3 days. After 2 weeks of culture, the
cells were fixed with methanol, stained either with 1% Alizarin Red S
(Sigma-Aldrich) to assess calcium phosphate deposition indicating
osteogenic differentiation or with Oil Red O (Sigma-Aldrich) to look
for lipid droplets indicating adipogenic differentiation [38].
Induction of endothelial cell differentiation. hPMSCs
were seeded at a density of 1610
3 cells/cm
2 in petri dishes and
cultured in endothelial cell growth medium 2 (EGM2; Promocell)
supplemented with Supplement Mix (Promocell) which contains
1 mg/ml ascorbic acid, 10 ng/ml human recombinant basic
fibroblast growth factor, 5 ng/ml human recombinant epidermal
growth factor, 22.5 mg/ml heparin, 0.2 mg/ml hydrocortisone,
20 ng/ml long R3 insulin like growth factor-1, 0.62 ng/ml phenol
red, 0.5 ng/ml human recombinant VEGF-A, and 2% FBS
(Hyclone). Additionally, 50 ng/ml VEGF-A (Chemicon) was
added to medium for induction of differentiation. The cultures
were maintained for 14 to 21 days and the culture medium was
replaced every three days [1,4].
Immunofluorescence staining
Immunofluorescence staining was performed as previously
described [20]. Primary antibody against specific proteins included
CD31 (JC70A; 1:50; Dako), CD34 (QBEND/10; 1:100; Serotec),
VE-cadherin (BV6; 1:100; Chemicon), vWF (1:200; Sigma-
Aldrich), CD105 (SN6h; 1:50; Dako), VEGFR-1 (Flt-1/EWC;
1:1000; abcam), VEGFR-2 (89106; 1:50; R&D Systems), integrin
b1 (HUTS-4; 1:1000; Chemicon), a4 (P4G9; 1:1000; Chemicon),
a5 (SAM-1; 1:100; Chemicon), anb3 (LM609; 1:100; Chemicon),
and anb5 (P1F6; 1:1000; Chemicon). Antibodies were diluted as
appropriate in 1% BSA in PBS. 49, 6-diamidino-2-phenylindole
(DAPI; Sigma-Aldrich) was used to identify nuclei.
Adhesion assay
The 24-well plates were coated with 10 mg/ml human
fibronectin (Upstate), vitronectin (Upstate), or 2.5% BSA (as a
control) at 37uC for one hour. After washing with PBS, the wells
were blocked with 2.5% (wt/vol) BSA in PBS at room temperature
for one hour. VEGF-A induced differentiated hPMSCs were
preincubated (30 min at 37uC) in HBSS containing either 3 mg/ml
non-specific mouse immunoglobulin (IgG; Dako) or a mouse
blocking monoclonal antibody specific to integrin b1 (HUTS-4;
Angiogenesis by Placenta Cells
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1:100; Chemicon), anb3 (LM609; 1:100; Chemicon), or anb5
(P1F6; 1:1000; Chemicon). A total of 6610
4 cells in 500 ml EGM2
supplemented with 0.2% BSA were seeded to the precoated wells
and allowed to adhere for 30 min at 37uC. Adherent cells were
quantified by counting in six randomly selected fields per well
(magnification 2006; Axiovert 200; Carl Zeiss MicroImaging).
Transwell migration assay
Cell migration assay were performed by 8-mm-pore transwells
(Costar). The VEGF-A induced differentiated hPMSCs were
preincubated (30 min at 37uC) in HBSS containing either 3 mg/ml
non-specific mouse IgG (Dako) or function-blocking mouse
monoclonal antibody specific to integrin b1 (HUTS-4; 1:1000;
Chemicon), a4 (P4G9; 1:1000; Chemicon), a5 (SAM-1; 1:100;
Chemicon), anb3 (LM609; 1:100; Chemicon), or anb5 (P1F6;
1:1000; Chemicon). A total of 5 to 8610
5 hPMSCs were added to
the upper chamber of the transwell and allowed to migrate for
20 hours at 37uC with EGM2 (600 ml; Promocell) in the presence
or absence of VEGF-A (50 ng/ml) together with either 0.5 to
50 mg/ml of fibronectin (Upstate) or vitronectin (Upstate) in the
lower chamber. The number of cells transmigrated to the lower
compartment was quantified by counting migrated cells in six
randomly selected fields per well (magnification 2006; Axiovert
200; Carl Zeiss MicroImaging).
In vitro angiogenesis
Induction of capillary tube formation was performed using an
In Vitro Angiogenesis kit (Chemicon) as recommended by the
manufacturer. VEGF-A-induced differentiated hPMSCs cells were
preincubated (30 min at 37uC) in HBSS containing either 3 mg/ml
non-specific mouse IgG (Dako) or function-blocking monoclonal
antibody specific to integrin b1 (HUTS-4; 1:1000; Chemicon), a4
(P4G9; 1:1000; Chemicon), a5 (SAM-1; 1:100; Chemicon), anb3
(LM609; 1:100; Chemicon), or anb5 (P1F6; 1:1000; Chemicon).
After blocking with these antibodies, cells were resuspended to
1610
5 cells/ml in EGM2, after which 100 ml/well of cell
suspension was added onto a gel of polymerized basement
membrane-like material (ECMatrix
TM). The cells were incubated
for 6 hours at 37uC for full development of capillary-like network
structures. Tube formation was quantified by counting the number
of polygonal tubes as well as cumulative tube length (long axis). In
instances where several tube-like structures merged together or
branched, the total length of the tubes was calculated as the sum of
the length of the individual branches [39]. Results are represented
as total tube length (mm) or number for six random photographic
fields per experimental condition (magnification 506; Axiovert
200; Carl Zeiss MicroImaging). The experiment was indepen-
dently repeated three times.
In vivo angiogenesis by chick chorioallantoic membrane
assay
The chick chorioallantoic membrane (CAM) assay was modified
from a prior report [40]. CAM was exposed by cutting a window
(2 cm
2) on one side of 10-day-old specific pathogen free chicken
eggs. A 3-mm-thick sterile straw disk, 8 mm in diameter, was
placed on the CAM for 3-dimensional culture on an area with a
minimum of small blood vessels. A total of 1610
5 of hPMSCs
pretreated either with anti-integrin b1 (HUTS-4; 1:1000; Chemi-
con), a4 (P4G9; 1:1000; Chemicon), a5 (SAM-1; 1:100; Chemicon)
or non-specific mouse IgG (1:50; Dako) and resuspensed in 100 ml
EGM2 were placed into the straw. The window in the shell was
sealed with adhesive tape and the egg was incubated for 48 hours.
Representative CAMs from each treatment group were photo-
graphed under a dissecting microscope (106) and counted. The
number of fine blood vessel branch points in the region of the
sample was counted. As angiogenesis is characterized by the
sprouting of new vessels in response to hPMSCs, counting blood
vessel branching points is a useful quantitative means of obtaining
an angiogenic index. At least 6 embryos were used per treatment
group. Data were evaluated in terms of average number of blood
vessel branching points per treatment group 6 SD. CAMs were
further excised, cryopreserved, cut into 5-mm sections, and
immunostained with vWF, CD31 and CD105 as described above.
For cell tracking, hPMSCs with or without induction into
endothelial differentiation by VEGF-A were labeled with green
fluorescence dye CellTracker
TM CMFDA (5 mM, Molecular
Probes, Invitrogen) before implanting into CAM. The CAM was
immunostained by primary antibody against human vWF (1:800,
Sigma-Aldrich) after cell transplantation. Quantification of new
vessel formation that contained hPMSC incorporation or the
number of hPMSCs that incorporated into the endothelia of each
vessel were conducted in 10 fields (4006) for each section from 3
randomly selected sections of each CAM tissue.
Statistical analysis
The measurements of counting were conducted blind by two
independent observers. The intra-class correlation coefficient for
intra- and inter-rater reliability of cell counts .0.75 was
considered good agreement. The data are described as means 6
SD. Differences were assessed using the independent-samples t
test, paired-samples t test, or Mann Whitney U test when
appropriate. A P value of less than 0.05 was considered significant.
The statistical software used is SSPS version 12.0 (Chicago,
IL,USA).
Results
Characterization of human placenta-derived multipotent
mesenchymal stromal cells
Flow cytometric analysis showed that hPMSCs were positive for
the multipotent mesenchymal stromal cell markers CD13, CD29,
CD44, CD54, CD73, CD90, CD105, and CD166, but negative
for the hematopoietic stem cell markers CD45 and CD34 and the
monocytic marker CD14 (Fig. 1A). These characteristics are
consistent with multipotent mesenchymal stromal cells. The cells
expressed HLA-ABC (MHC I), but not HLA-DR (MHC II;
Fig. 1A). hPMSCs were also positive for the embryonic stem cell-
associated cell surface marker stage-specific embryonic antigen
(SSEA)-4 (38.2610.4%), and the pluripotent stem cell-specific
transcription factor Oct-4 (78.4611.5%). However, hPMSCs do
not express SSEA-1 (Fig. 1A), TRA-1-60, or TRA-1-81 (not
shown). The absence of CD34 in the hPMSC isolate excludes
endothelial cell contamination. Flow cytometry analysis further
showed hPMSCs to express integrins av, a4, a5, b1, b3, and b5,
while b2 and b4 were undetectable (Fig. 1C).
RT-PCR analysis of total RNA from cultured hPMSCs showed
expression of Oct-4, Nanog and Sox-2, transcription factors
associated with pluripotency [41–43] (Fig. 1B). hPMSC multi-
potency was demonstrated using standard osteocyte and adipocyte
differentiation assays. In the former case hPMSCs formed nodules
and stained with Alizarin Red S, indicating calcium salt
crystallization and osteogenic differentiation (Fig. 1D). In the
latter assay, hPMSCs developed Oil Red O–positive cytoplasmic
lipid droplets indicating adipocyte differentiation (Fig. 1E). This
was not seen in control cells (Fig. 1F).
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hPMSCs were cultured in the presence of EGM2 with 2% FBS and
50 ng/ml VEGF-A for 14 to 21 days, then stained with antibodies to
the endothelial markers: CD31, CD34, VE-cadherin, VEGFR-1,
VEGFR-2, vWF, and CD105, and assayed by flow cytometry (Fig. 2).
Undifferentiated hPMSCs cultured with regular medium showed no
significant immunofluorescence staining for CD31 (Fig. 2A), CD34,
VE-cadherin or vWF (not shown). The overall fluorescence intensity of
CD31 (Fig. 2B), CD34 (Fig. 2C), VE-cadherin (Fig. 2D), VEGFR-1,
VEGFR-2 and vWF (Fig. 2E–H) in differentiated hPMSCs was
markedly enhanced after 21 days of cultivation, indicating the
differentiation of hPMSC to endothelial cells. Weibel-Palade bodies
were clearly visible within differentiated hPMSCs under high
magnification (Fig. 2H). CD105 was expressed in differentiated
h P M S C s( F i g .2 J ) .H o w e v e r ,t h eu n d i f f e r e n t i a t e dc e l l sw e r ea l s o
positive for CD105 (Fig. 2I). Flow cytometry revealed a substantial
increase of expression of CD31 (3.161.6% vs. 56.6611.4%;
P=0.012), CD34 (1.261.0% vs. 46.3614.1%; P=0.029), VE-
cadherin (0.860.7% vs. 14.164.4%; P=0.038), VEGFR-1
(1.561.1% vs. 27.066.2%; P=0.015), VEGFR-2 (1.961.0% vs.
46.462.7%; P=0.001) and vWF (0.860.7% vs. 63.267.1%;
P=0.004), but not CD105 (94.666.3% vs. 88.168.3%; P=0.825)
in differentiated hPMSCs compared to control cells (Fig. 2K).
Endothelial differentiation of hPMSCs was further revealed by
mRNA analysis. Two different strains of hPMSCs were used for
comparison before and after differentiation. Consistent with a
previous report [5], the hPMSCs express various hematopoietic
genes. Transcription from the CD34 and CD105 genes was
variable between hPMSC isolates. However, after differentiation,
the cells showed increased levels of mRNA encoding CD31, VE-
cadherin, VEGFR-1, VEGFR-2, and vWF (Fig. 2L).
Immunofluorescence staining demonstrated integrins a4, a5, b1,
avb3, and avb5 in undifferentiated hPMSCs. Integrin a5 (Fig. 3E,
3F) and b1 (Fig. 3A, 3B) were significantly increased after
endothelial differentiation, but not integrin a4 (Fig. 3C, 3D), avb3
(Fig. 3G, 3H), or avb5 (Fig. 3I, 3J). Cell surface levels of integrin av,
a4, a5, b1, b3, and b5 subunits were assayed by flow cytometry
before and after endothelial differentiation. Mean specific fluores-
cence (which corresponds to the increase in fluorescence intensity
relative to second antibody alone) was higher for both integrins a5
and b1 in differentiated hPMSCs (Fig. 3K, 3L). This suggests a
significant increase in cell surface integrin a5b1 expression as the
cells differentiated. In contrast, no increase was observed in
expression of the avb3o ravb5 integrin, which have also been
implicated in binding of fibronectin, vitronectin and other RGD–
containing ligands, and in angiogenesis [21,44,45].
Figure 1. Characterization of human placental multipotent mesenchymal stromal cells (hPMSCs). (A) Flow cytometry analysis of cell-
marker expression by hPMSCs. The cells express CD13, CD29, CD44, CD54, CD73, CD90, CD105, CD166, HLA-ABC, Oct-4, and SSEA-4, but are negative
for HLA-DR, CD34, CD45, and SSEA-1. The shaded area shows the profile of the cells stained by a control antibody of matching isotype. Ten thousand
cells were counted from each sample. (B) Analysis of stem cell markers on hPMSCs by RT-PCR analysis. Three different strains of hPMSCs are shown in
lane 1 to 3. Lane 4 was RNA obtained from a human embryonic stem cell line (hES 6; ES Cell International, USA) and served as a positive control. PCR
was performed for 35 cycles to demonstrate Oct-4 and Sox-2 transcripts, and 30 cycles for Nanog. (C) The expression of integrin subunits on hPMSCs
determined by flow cytometry. The data shown are representative of 3 different experiments. (D) Osteogenic differentiation of hPMCs resulted in
positive staining for Alizarin Red S, indicating the presence of calcium salt deposition associated with the matrix. (E) Adipocyte differentiation resulted
in cytoplasmic lipid droplets that were Oil Red O–positive. (F) Undifferentiated hPMSCs used as a control for Oil Red O staining. The cells were
counterstained with Mayer’s hematoxylin (E, F). Scale bar: 100 mm.
doi:10.1371/journal.pone.0006913.g001
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differentiated hPMSC adhesion and migration
Since integrin a5b1 is a specific receptor for fibronectin, and
angiogenesis often involves endothelial cell adhesion and migration
within a fibronectin-rich ECM, we investigated the ability of
differentiated cells to interact with fibronectin. As the cells also express
integrins avb3 and avb5, vitronectin was used as a control ligand.
Differentiated hPMSCs adhered to fibronectin more efficiently than to
vitronectin (P,0.001). VEGF-A significantly increased the adhesion of
differentiated hPMSCs to fibronectin but not to vitronectin- or BSA-
coated plates (Fig. 4A). Significant inhibition of differentiated hPMSC
attachment to fibronectin-coated plates was observed in the presence of
blocking antibodies to integrin a5 and b1, whereas very limited
inhibition effect was observed in the presence of antibody to avb3 and
avb5. Attachment to vitronectin was low, and blocking antibodies had
no significant effect (Fig. 4B). These experiments indicated that integrin
a5b1on the surface of differentiatedhP M S C si si m p or ta ntf o rm e di a ti ng
cell attachment to fibronectin, with a further contribution from avb3.
Migration of differentiated hPMSC was enhanced by either
VEGF-A (50 ng/ml) or fibronectin (50 mg/ml) alone, but the
Figure 2. Characterization of human placental multipotent mesenchymal stromal cells (hPMSCs) after inducing differentiation into
endothelial cells. Immunofluorescence staining of CD31 in undifferentiated hPMSCs is shown in (A) as a negative control. Immunofluorescence of
endothelial markers in differentiated hPMSCs under induced culture conditions: (B) CD31, (C) CD34, (D) VE-cadherin, (E) VEGFR-1, (F) VEGFR-2, (G) von
Willebrand factor, (H) von Willebrand factor under high magnification (Scale bar: 1 mm); Weibel-Palade bodies were visible within the differentiated
hPMSC cytoplasm (arrow). CD105 was positive in (I) undifferentiated hPMSCs and (J) hPMSCs differentiated into endothelial cells. Cell nuclei were
counterstained with DAPI. Scale bar: 10 mm. (K) Flow cytometry analysis of endothelial cell markers on the hPMSC surface before and after
differentiation induced by VEGF-A. (L) mRNA for endothelial cell markers was amplified from 2 different strains of undifferentiated hPMSCs (lane 1 and
2) and hPMSCs differentiated into endothelial cells (lane 3 and 4). mRNA from human umbilical vein endothelial cells was used as a positive control
(lane 5). The data shown are representative of 3 different experiments.
doi:10.1371/journal.pone.0006913.g002
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effect (Fig. 4C). In contrast, neither vitronectin alone nor the
combination of VEGF-A and vitronectin promoted migration
(Fig. 4C). In the presence of antibodies to integrin a5 or b1, cell
migration to VEGF-A and fibronectin together was suppressed,
whereas antibodies to a4, avb3,o ravb5 had no effect (Fig. 4D).
These results suggest strongly that enhanced adhesion and
migration of differentiated hPMSC in the presence of VEGF-A
and fibronectin are dependent on integrin a5b1.
The ability of differentiated hPMSCs to form capillary-like
structures is mediated by integrin a5b1
To study the molecular mechanisms underlying capillary-like
morphogenesis in differentiated hPMSCs, either differentiated
Figure 3. Integrin expression at the surface of human placental multipotent mesenchymal stromal cells (hPMSCs) before and after
inducing differentiation into endothelial cells. Undifferentiated hPMSCs: A, C, E, G, I; differentiated hPMSCs: B, D, F, H, J. The cells were
immunostained using antibody against integrin (A, B) b1, (C, D) a4, (E, F) a5, (G, H) avb3, or (I, J) avb5. Scale bar: 10 mm. Immunofluorescence staining
revealed significant increases in integrin a5 and b1. (K) The change of hPMSC surface integrin expression after differentiation induced by VEGF-A was
measured by flow cytometry and expressed in fluorescence intensity units. Change in fluorescence intensity is an index of integrin surface
concentration per cell. (L) Quantification of specific mean fluorescence intensity (which corresponds to the increase in fluorescence intensity relative
to second antibody alone) is shown (6SD, n=3). The specific mean fluorescence intensity was higher for both integrins a5 and b1 in differentiated
hPMSCs. C: controls; E: endothelial cell differentiation induced by VEGF-A.
doi:10.1371/journal.pone.0006913.g003
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were seeded onto a basement membrane-like gel. HUVEC
(Fig. 5A) and undifferentiatedh P M S C s( F i g .5 B )w e r eu s e da s
positive and negative controls, respectively. The undifferentiat-
ed hPMSCs showed very few capillary-like structures after
6 h o u r s ,a n dm o s tc e l l sr e m a i n e dr o u n d e d( F i g .5 B ) .T h e
differentiated hPMSCs typically showed cytoplasmic projec-
tions, spikes and extensions, and had elongated within 6 hours,
with most cells becoming integrated into capillary-like structures
(Fig. 5C). Formation of these structures was strongly inhibited in
t h ep r e s e n c eo fa n t b o d i e st oi n t e g r i nb1 (Fig. 5D) or a5 (Fig. 5F).
Blocking antibodies to integrin a4, avb3,o ravb5 did not show
inhibitory activity (Fig. 5E, 5G, 5H; quantified in Fig. 5M).
Immunostaining confirmed that cells in the capillary-like
structures express the specific endothelial markers including
vWF (Fig. 5J), CD31 (Fig. 5K), and CD105 (Fig. 5L).
Figure 5I was the cells stained by non-specific IgG as a
control.
Figure 4. Adhesion and migration assays were performed with human placental multipotent mesenchymal stromal cells (hPMSCs)
and various integrin-blocking antibodies. (A). hPMSCs were induced to differentiate into endothelial cells, then plated onto surfaces coated
with BSA (NC), fibronectin, or vitronectin in the presence or absence of VEGF-A. The differentiated hPMSCs adhered to fibronectin more efficiently
than to vitronectin (P,0.001). VEGF-A significantly increased the adhesion of differentiated hPMSCs to fibronectin but not to vitronectin or plates
coated with 2.5% BSA solution (NC). (B) Inhibition of differentiated hPMSC adhesion to fibronectin and vitronectin in the presence of blocking
antibodies to integrin subunits. A significant inhibition of differentiated hPMSC adhesion to fibronectin was observed in the presence of blocking
antibodies to integrin a5, b1 or avb3, but not integrin avb5. The number of differentiated hPMSCs attached to vitronectin was low. (C) Transwell
migration of differentiated hPMSCs induced by VEGF-A (50 ng/ml) with or without fibronectin (0.5 to 50 mg/ml) or vitronectin (0.5 to 50 mg/ml).
Fibronectin in the presence of VEGF-A stimulated migration. (D) Inhibition of differentiated hPMSC transwell migration induced by VEGF-A (50 ng/ml)
with or without fibronectin (50 mg/ml). Various blocking antibodies to integrin subunits and non-specific IgG were used. Antibodies to integrin
subunits a5 and b1 were inhibitory. Error bar: SD; Ab: antibody; ECM: extracellular matrix.
doi:10.1371/journal.pone.0006913.g004
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e6913Figure 5. In vitro angiogenesis: formation of capillary-like structures by differentiated human placental multipotent mesenchymal
stromal cells (hPMSCs). hPMSCs were trypsinized, seeded on wells coated with ECMatrix
TM. (A) Human umbilical vein endothelial cells and (B)
undifferentiated hPMSCs were used as positive and negative control (shown after 6 hours of culture). (C) hPMSCs induced to differentiate into
endothelial cells form characteristic capillary-like structures. Cell elongation and cell interconnecting cell networks were observed. Differentiated
hPMSCs were pretreated with antibodies against (D) integrin b1, (E) a4, (F) a5, (G) avb3, or (H) avb5. Scale bar: 200 mm. Representative
photomicrographs of 3 different experiments are shown. This ability of differentiated hPMSCs to form capillary-like structures was strongly
diminished when integrin b1 or a5 was inhibited. Blocking antibodies to integrins a4, avb3,o ravb5 did not inhibit the formation of capillary-like
structures. The capillary-like structures on ECmatrix
TM gel were immunostained using antibody against (I) non-specific IgG or specific endothelial
markers (J) von Willebrand factor, (K) CD31, and (L) CD105. Scale bar: 50 mm. Arrows indicate von Willebrand factor, CD31 and CD105 positive cells
present in ECmatrix
TM gel. (M) Quantification of the capillary-like structures by measuring the polygonal network (upper panel) and the cumulative
tube length (lower panel) formed by differentiated hPMSCs. A significant inhibition of capillary-like structure formation was observed when integrin
b1 or a5 antibody was applied to the cells. Error bar: SD.
doi:10.1371/journal.pone.0006913.g005
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hPMSCs in vivo
Differentiated or undifferentiated hPMSCs were implanted onto
CAMs of ten-day-old chick eggs, and two days later the CAM was
imaged (Fig. 6A–G) and vessel branching points counted (Fig. 6H).
In contrast to the short-term incubation in vitro, the transplanted
undifferentiated hPMSCs augmented angiogenesis (Fig. 6B, 6H).
However, there was a statistically significant increase of neovas-
cularization in the CAM transplanted by differentiated hPMSCs
compared to that of undifferentiated hPMSCs or control (Fig. 6A–
C and 6H). The angiogenic activity of the differentiated hPMSCs
was significantly reduced by preincubation with anti-integrin a5 or
b1 prior to transfer to the CAM (Fig. 6D and 6F). Addition of anti-
integrin a4 or non-specific mouse IgG antibody had no significant
effect on angiogenic activity (Fig. 6E and 6G). Immunostaining of
the CAM further revealed cells within the neovessels were positive
for human vWF, CD31 and CD105 (Fig. 6J–L). The CAM
without hPMSC transplantation was vWF negative (Fig. 6I). These
results demonstrated that the differentiated hPMSCs contributed
to the neovascularization of CAM and the angiogenic activity is
mediated through integrin a5 and b1.
To assess hPMSC distribution after transplantation, differenti-
ated hPMSCs were found distributed widely in CAM vasculature
(Fig. 6O, 6Q). Immunofluorescence demonstrated a part of these
incorporated hPMSCs labeled with CellTracker
TM CMFDA
expressed endothelial cell-specific protein vWF (Fig. 6M, 6O). A
significantly higher number of vessels of CAM contained hPMSCs
after transplantation with differentiated hPMSCs compared to
undifferentiated cells (79.4611.7% vs. 45.5616.5%; P=0.001;
Fig. 6Q), and differentiated hPMSCs were significantly more
numerous in the vessels than undifferentiated cells (81.168.2% vs.
38.769.2%; P,0.001; Fig. 6R).
Discussion
hPMSCs have the potential to differentiate into endothelial cells
under appropriate conditions both in vitro and in vivo. The
differentiated cells express a panel of endothelial cell makers
including vWF, CD31, CD34, VE-cadherin and the endothelial
cell receptors VEGFR-1 and VEGFR-2 in vitro and in vivo. They
can form capillary tube-like structures in vitro and have a greater
capacity to augment angiogenesis in the CAM assay than
undifferentiated cells. The ability of differentiated hPMSCs to
form new blood vessels involves integrin b1 and a5, but not
integrin av, a4, b3,o rb5.
In agreement with previous reports [5–8], the phenotype of
hPMSC is similar to that of human bone marrow-derived
multipotent mesenchymal stromal cells [31,46]. Although undif-
ferentiated hPMSCs express various hematopoietic gene tran-
scripts [5], they do not bear the hematopoietic marker CD45.
They express adhesion molecules and mesenchymal stem cell
markers, including CD29, CD44, CD73, CD105, and CD166
[47,48]. We also observed that hPMSCs express genes that are
considered to be specific to pluripotent embryonic cells [41–43]
such as Oct-4 and SSEA-4. SSEA-4 was previously thought to
mark specifically human embryonic stem cells, but has also been
observed in subpopulations of adult bone marrow-derived or
placenta-derived multipotent mesenchymal stromal cells [6,49,50].
Fibronectin and VEGF-A are important regulators of blood
vessel growth [51,52]. Fibronectin is highly expressed within the
hematopoietic microenvironment [53] and is involved in the
adhesion of hematopoietic stem and progenitor cells [12,54,55].
Fibronectin acts as a ligand for integrins a5b1, a4b1 and avb3
[21,44,56–58]. However, hPMSC adhesion to, and migration on
fibronectin are specifically dependent on subunits b1 and a5, the
expression of both subunits increases upon endothelial differenti-
ation, and angiogenesis is inhibited by blocking either of these two
subunits. Hence we suggest the heterodimer a5b1 interacts with
fibronectin in the pericellular matrix to mediate key steps in
angiogenesis. VEGF-A and fibronectin together significantly
promote the adhesion and migration of hPMSCs. This augmen-
tation effect is specific to fibronectin and the a5b1 integrin.
Alterations of integrin expression may contribute to angiogen-
esis. It has been found that VEGF-A increases the migration of
human dermal microvascular endothelial cells through the
upregulation of avb3 integrin expression [59]. Cells undergoing a
TGF-b-induced angiogenic program up-regulate integrin a5 [60].
A significant up-regulation of a5 subunit expression in vascular
cells participating in choroidal neovascularization of injured eye
was observed [61]. Furthermore, during the early phase of vessel
sprouting, when interacting with fibronectin-rich interstitial ECM,
activated endothelial cells may utilize integrin a5b1 or avb3 to
mediate the angiogenic response, later switching to other integrin
subunits once basement membrane ligands such as laminin have
assembled around the new vessel [62–65]. These reports suggest
that a5b1 or avb3 may play a role in neovascularization and
provide a target for therapeutic intervention [61,66]. We observed
that VEGF-A increased the expression of integrin a5b1, but not
avb3 or avb5.
Targeted gene ablation reveals that successful vasculogenesis
dependsonintegrina5b1[18]anditsligand fibronectin[16,67],and
is not strongly dependent on integrin avb3 [18]. Homozygotic
integrin a5-deficient mouse embryos demonstrate vascularization
disruption and die in utero with numerous morphological defects
[15]. Fibronectin-deficient mice also develop defects in the yolk sac
vasculature [16,67]. In integrin a5-null embryonic cells, develop-
ment of a complex vasculature is hindered with reduced cell
proliferation and increased apoptosis [17]. Integrin b1 is required
for the initiation of basement membrane formation. In integrin b1-
null embryonic bodies, the complex vasculature formation is
significantly delayed [68]. In contrast, vasculogenesis and angio-
genesis in virtually all organs develop normally in av-null embryos
[69]. Mice lacking b3 integrins or both b3 and b5 integrins not only
enhance tumor growth, but have enhanced angiogenesis. Thus,
neither b3 nor b5 integrins are essential for neovascularization [70].
Furthermore, both b3-null and b5-null mice are viable, with
unaffected developmental angiogenesis and adult angiogenesis such
as retinal neovascularization and wound healing [71,72]. These
reports support our observations that angiogenesis by differentiated
hPMSCs is independent of integrin av, b3 and b5.
In contrast to the short incubation period of in vitro
angiogenesis assays, both undifferentiated and differentiated
hPMSCs were observed to enhance angiogenesis in the CAM
assay. hPMSCs with positive vWF staining were observed to
engraft in the endothelium of CAM. Direct integration of
hPMSCs into CAM vasculature may augment sprouting angio-
genesis. Similar to the study of ischemic brain or heart,
multipotent mesenchymal stromal cells widely incorporated into
vasculature and a subset of them was capable of differentiating into
endothelial cells [73,74]. However, hPMSCs after inducing
endothelial cell differentiation have more cell numbers incorpo-
rated into CAM vessel and have a significantly greater angiogenic
effect than that of undifferentiated hPMSC. Additionally, we
cannot exclude other specific adhesion molecules or growth factors
which may regulate distinct angiogenic responses. The paracrine
factors expressed by hPMSCs may participate in enhancing
angiogenesis other than the transdifferentiation into endothelial
cells by hPMSCs [75].
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PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e6913Figure 6. Stimulation of angiogenesis in chick chorioallantoic membrane (CAM) by undifferentiated or differentiated human
placental multipotent mesenchymal stromal cells (hPMSCs). Small tortuous blood vessels, typical of neovascularization, were visible in the
CAM. The development of new blood vessels was determined by counting branch points (arrows) after 48 hours of cell transplantation. Sprouting
and branching vessels (arrows) are prominent in the CAM transplanted by (C) differentiated hPMSCs compared to the (A) negative control (fresh
culture medium) without hPMSC transplantation and (B) undifferentiated hPMSCs transplantation. CAMs were implanted by differentiated hPMSCs
pre-treated with antibodies against integrin (D) b1, (E) a4, (F) a5, or (G) non-specific IgG. Scale bar: 3 mm. Representative photomicrographs of 6
different chicken embryos are shown. (H) Quantification of new blood vessels formed by negative control (NC; fresh culture medium) or hPMSCs in
CAM. The angiogenic effect was substantially reduced in hPMSCs pre-treated with anti-integrin a5 or b1 antibody. Cryosections of CAMs were
immunostained by (I) von Willebrand factor (vWF), (J) vWF, (K) CD31, and (L) CD105 antibodies. (I) CAM without hPMSC transplantation was negative
for vWF staining, indicating human vWF antibody does not cross react with CAM. (J–L) Arrows indicated vWF, CD31 and CD105-positive cells present
in CAM, revealing that differentiated hPMSCs contributed to neovascularization. CAM transplanted with (M) undifferentiated hPMSCs or (O)
differentiated hPMSCs were immunostained using a rhodamine (red)-conjugated human vWF antibody. The hPMCs were labeled with CellTracker
TM
CMFDA (green). DAPI (blue) staining was used to identify nuclei. The incorporation of hPMSC into CAM endothelium that expressed vWF would
reveal yellow signal. Differentiated hPMSCs were widely incorporated into endothelium of CAM vessels (O). A large arrow indicates the hPMSCs
incorporated into CAM vessel endothelium. A small arrow indicates a nearby vessel lacking both engrafted hPMSCs and human vWF expression (M).
Plenty of nucleated red blood cells were observed within the lumens of vessels. (N, P) Hematoxylin-eosin stained serial sections with inset areas
matching images of M and O. Scale bar: 50 mm. (Q) Quantification of the number of new vessels formation that contained hPMSCs after
transplantation of differentiated or undifferentiated hPMSCs. (R) Quantification of the number of hPMSCs incorporated into vessel endothelium after
transplantation of differentiated or undifferentiated hPMSCs. D hPMSCs: differentiated hPMSCs; U hPMSCs: undifferentiated hPMSCs; Error bar: SD.
doi:10.1371/journal.pone.0006913.g006
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PLoS ONE | www.plosone.org 10 October 2009 | Volume 4 | Issue 10 | e6913Our results are the first to identify a role for integrins in the
regulation of angiogenesis initiated by hPMSCs. hPMSCs are a
useful model to study the role of VEGF-A in differentiation and
maturation of endothelial cells, and the role of integrins during
placental angiogenesis and vasculogenesis. Transplantation of
hPMSCs may offer potential for treating ischemic diseases.
Transplantation of hPMSCs to the ischemic limbs of SCID mice
significantly improved blood vessel formation and blood flow in
the affected limbs [76]. In addition these cells could be utilized in
the engineering of complex tissues in whcih vascularization is an
essential feature.
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